Actiphage

PBD Biotech, developers of Actiphage® TB, a ground-breaking phage-based diagnostic for laboratory tuberculosis testing, has today announced it has secured the grant of a US patent for its diagnostic kit.

Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been revealed by the TAG pipeline report

A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.

Jee-Whang Kim of Leicester Tuberculosis Research Group (LTBRG) is to present a paper in the ‘hot topics in tuberculosis’ session at ECCMID 2022

Of the 10 million individuals who became ill with 'active' TB in 2018, approximately three million were missed by health systems, according to the Centres for Disease Control and Prevention (CDC)